Search Bar & Filters
Found 22 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatments for metastatic castration-resistant prostate cancer mCRPC. This study evaluates the medicine ifinatamab deruxtecan I-DXd or MK-2400 compared to chemotherapy to see if it helps people live longer overall and without cancer progression. The trial is sponsored by Merck Sharp & Dohme LLC and focuses on men with advanced prostate cancer who have tried other therapies. Participants are randomly assigned to one of two groups. One group receives I-DXd at 12 mg per kg every three weeks through intravenous infusion, along with premedication to prevent nausea and vomiting. The other group receives docetaxel chemotherapy at 75 mgm every three weeks plus daily oral prednisone. Treatments continue until the cancer worsens, side effects are unacceptable, or treatment stops for other reasons. During the study, participants will have regular assessments to monitor overall survival and how long they live without cancer progression, up to about 36 months. Researchers will also track additional outcomes like time to subsequent therapies, response rates, pain progression, and side effects. Safety and treatment tolerability will be closely monitored throughout the trial, which may last up to six years for some participants.
Actively Recruiting
Researchers are evaluating HMBD-001, an anti-HER3 antibody, in combination with cetuximab with or without docetaxel for people with advanced squamous cell cancers. This Phase IbII, open-label, multi-center study focuses on various types of advanced or metastatic squamous cell carcinomas, including lung, head and neck, esophageal, cervical, cutaneous, and nasopharyngeal cancers. The study aims to assess the safety and effectiveness of these treatments in participants who have limited standard care options. Participants receive HMBD-001 intravenously once a week alongside cetuximab weekly, with or without docetaxel administered every three weeks. There are three treatment arms one with HMBD-001 plus docetaxel, one with HMBD-001 plus docetaxel and cetuximab both closed to recruitment, and one with HMBD-001 plus cetuximab. The trial evaluates different combinations to understand their effects on advanced squamous cell cancers. During the study, participants are monitored for adverse events and dose-limiting toxicities. Researchers track progression-free survival up to six months and measure tumor response using established criteria. Blood samples are collected to study the drugs behavior in the body and immune response. The study includes repeated treatment cycles and safety follow-up, with assessments continuing up to 48 months. Participants undergo tumor biopsies and organ function tests to ensure safety and gather comprehensive data.
Actively Recruiting
Researchers are studying the safety, tolerability, and best dosing of a drug called ABT-301 combined with fixed doses of tislelizumab and bevacizumab in adults with a type of colorectal cancer called proficient mismatch repair pMMRnon-microsatellite instability-high non-MSI-H colorectal cancer. This study aims to find the highest safe dose of ABT-301 and the recommended dose for future studies while evaluating its effects in advanced or metastatic cases. Participants will take ABT-301 orally either once or twice daily in 21-day treatment cycles. Alongside ABT-301, participants will receive tislelizumab 200 mg and bevacizumab 7.5 mgkg via intravenous infusion on the first day of each 21-day cycle. The study has two parts a dose-escalation phase to identify safe dosing levels and a dose-optimization phase to further evaluate two selected doses for safety and activity against the cancer. During the study, participants will undergo regular assessments including measuring tumor response using RECIST criteria, monitoring safety and side effects, and pharmacokinetic and pharmacodynamic evaluations. These assessments occur from screening through treatment and up to 90 days after the last dose or until disease progression or death, lasting up to 28 months. The study monitors overall survival, progression-free survival, and duration of response to treatment.
Actively Recruiting
Researchers are studying how well Immune Globulin Infusion IGI, 10% can help prevent infections in adults with multiple myeloma who are receiving a special bispecific antibody therapy targeting B-cell maturation antigen BCMA and CD3. The trial compares two groups one receiving IGI, 10% regularly for 12 months as primary infection prevention, and the other receiving IGI, 10% only if they develop a serious infection during the study period. This is a Phase 3, randomized, open-label study sponsored by Takeda. Participants will be randomly assigned to either receive IGI, 10% intravenously every 3 or 4 weeks for 12 months regardless of infections or receive it only after experiencing at least one serious infection during the 12-month observation. The dosing is based on standard care, with a dose of 400 mgkg given within 3 days after randomization. The study design includes 15 to 19 clinic visits depending on dosing intervals. During the study, participants will be monitored for serious infections and other infection-related outcomes up to 12 months. Researchers will measure the time to first serious infection as the primary outcome, along with rates of infections, antibiotic use, hospitalizations, and immune response markers such as immunoglobulin G levels. Safety will also be assessed by tracking adverse events related to IGI, 10%. Total participation lasts up to 14 months including an approximately 8-week screening period.
Actively Recruiting
Researchers are studying the combination of JNJ-87189401 and JNJ-78278343 in men with advanced prostate cancer to find the best dosing regimen and evaluate the safety of these drugs alone or combined with other treatments. The study includes several parts to determine the recommended phase 2 doses and assess safety when adding apalutamide, lutetium Lu-177 vipivotide tetraxetan, or JNJ-101556143. This Phase 1 trial aims to improve treatment options by carefully monitoring participants responses and side effects. Participants receive the study drugs in different parts Part 1 involves dose escalation to select the recommended regimen, Parts 2A and 2B involve treatment at that regimen, and Part 2C adds apalutamide. Part 3 combines the study drugs with standard lutetium treatment, adjusting doses as needed. Part 4 evaluates the combination with JNJ-101556143, also with dose escalation to find the best regimen. The study drugs are given sequentially, with safety closely monitored throughout. During the trial, participants undergo assessments including monitoring for dose-limiting toxicities and adverse events for up to 4 years and 8 months. Researchers measure drug concentrations in blood, antibody responses, tumor responses, progression-free survival, prostate-specific antigen levels, and duration of response. The study involves regular visits and evaluations to track safety and effectiveness, with participation lasting several years to gather comprehensive data.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and effectiveness of Imzokitug combined with Pumitamig and Platinum-Doublet Chemotherapy PDCT compared to Pumitamig and PDCT alone as first-line treatment for adults with locally advanced or metastatic Non-Small Cell Lung Cancer NSCLC. This Phase 2, randomized, open-label study is sponsored by Bristol-Myers Squibb and focuses on patients with stage IV or recurrent unresectable NSCLC. Participants are randomly assigned to one of several treatment groups receiving combinations of Pumitamig, Imzokitug, and histology-based PDCT drugs such as Pemetrexed, Cisplatin, Carboplatin, or Paclitaxel. Each drug is given in specified doses on designated days. The study compares the combination therapies over the treatment period to assess their impact on the cancer. During the trial, participants undergo assessments including tumor measurements using the RECIST v1.1 criteria to determine objective response rate and progression-free survival, along with monitoring for adverse events up to 90 days after treatment ends. The study also tracks overall survival, duration of response, and time to recurrence for up to about four years. Participants will be regularly evaluated by investigators throughout the study duration, which extends to the study completion date in 2030.
Actively Recruiting
Researchers are evaluating the efficacy and safety of pegozafermin in adults aged 18 to 75 years who have biopsy-confirmed and clinically confirmed compensated cirrhosis caused by metabolic dysfunction-associated steatohepatitis MASH. This phase 3 study aims to compare pegozafermin against a matched placebo to better understand its effects on liver fibrosis and disease progression in this population. Participants will receive either pegozafermin or a placebo through subcutaneous injections. The study is randomized and quadruple-blinded, ensuring neither participants nor researchers know which treatment is given. Treatment effects will be observed over a period of up to 5 years, with primary outcomes measured at 24 months, including fibrosis regression and time to disease progression based on specified clinical events. Throughout the study, participants will undergo regular assessments, including liver function tests like ALT and AST, enhanced liver fibrosis scores, FibroScan elastography, and evaluations for portal hypertension and other liver-related complications. Safety monitoring will track adverse events during the treatment and follow-up period. The trial spans several years, allowing long-term observation of treatment outcomes and participant health.
Actively Recruiting
Researchers are evaluating a modified interleukin-2 fusion protein called IOV-3001 in adults with previously treated, unresectable or metastatic melanoma who will receive lifileucel. This Phase 12, open-label study aims to understand the safety, tolerability, and appropriate dosing of IOV-3001, which incorporates a modified form of aldesleukin into the antibody palivizumab. The trial includes participants with melanoma that has progressed after certain prior therapies and focuses on both cutaneous and uveal melanoma under specific conditions. Participants will receive IOV-3001 as a single intravenous infusion administered in a hospital setting. The Phase 1 portion has two parts in Part 1, IOV-3001 is given before the lifileucel treatment regimen in Part 2, it is given after lifileucel instead of aldesleukin. Dose escalation will occur in participants with unresectable or metastatic melanoma to determine the recommended dose for Phase 2. During the study, participants will be closely monitored for safety and pharmacokinetics up to 30 days after dosing, with longer-term follow-up to assess immune response, overall and progression-free survival, and response rates for up to 5 years. Researchers will evaluate treatment effects using radiographic assessments, immune profiles, and disease progression measures. Safety follow-up and data collection will continue after treatment to better understand the therapys impact and persistence.
Actively Recruiting
Researchers are evaluating the safety, pharmacokinetics, and preliminary effectiveness of NST-628, an oral drug targeting the MAPK pathway, in adults with advanced solid tumors that have specific genetic mutations and have exhausted standard treatments. This Phase 1, open-label, multi-center study includes patients with tumors dependent on the MAPK pathway, such as melanoma and glioma, aiming to find a suitable dose and observe tumor responses. The study has two parts Part A involves dose escalation where increasing doses of NST-628 are given once daily in 28-day cycles to determine the maximum tolerated dose and the recommended dose for expansion. Part B involves dose expansion with several cohorts of patients harboring specific MAPK pathway mutations receiving the recommended dose to further assess safety and tumor response. Dose adjustments may be made based on observed effects. Participants will undergo regular assessments including safety evaluations, tumor response measurements using standardized criteria, and pharmacokinetic analyses throughout the study, which lasts about one year on average for primary outcomes and up to two years for survival monitoring. Tumor tissue samples are required, and patients will be followed until the last visit of the final participant. Safety, tumor response, progression-free survival, overall survival, and drug behavior in the body are key outcomes measured.
Actively Recruiting
Researchers are evaluating the study medicine elranatamab, alone and combined with daratumumab, in people with multiple myeloma who have previously been treated with therapies including lenalidomide. The trial aims to determine whether elranatamab offers more benefit compared to a combination therapy of daratumumab, pomalidomide, and dexamethasone, while also assessing the safety and activity of elranatamab with daratumumab. This is a Phase 3, randomized, open-label study designed to compare these treatment options and to evaluate infection protection measures. The study includes three parts. Part 1 tests the safety and activity of different doses of elranatamab combined with daratumumab. In Part 2, participants are randomly assigned to receive elranatamab alone, elranatamab plus daratumumab, or the combination of daratumumab, pomalidomide, and dexamethasone. Part 3 assesses the impact of enhanced infection protection in participants receiving elranatamab alone or with daratumumab. Treatments are administered subcutaneously or orally as appropriate, and participants continue treatment until disease progression, unacceptable side effects, or withdrawal. Participants will undergo regular assessments including monitoring of disease progression, safety evaluations, and adverse event tracking. Key outcome measures include dose-limiting toxicities, progression-free survival, and treatment-emergent adverse events. Other evaluations include overall survival, response rates, duration of response, pharmacokinetics, immunogenicity, and quality of life assessments. Follow-up and monitoring continue for up to 51 months after randomization to capture long-term effects and safety.
1-10 of 22
1